Autopsy report · NCT00003513

Antineoplaston Therapy in Treating Patients With Metastatic, Recurrent, or Refractory Neuroblastoma

“slow accrual”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 years 11 months after it had already started.
• Ran for about 2 years 3 months before it stopped.
• 3 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Burzynski Research Institute

Sponsor type

University, hospital or other

Conditions

Neuroblastoma

Interventions

Antineoplaston therapy (Atengenal + Astugenal)

Participants

3

Sites

1

Countries

United States

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.